Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma

por Bergerot, Cristiane Decat, Battle, Dena, Bergerot, Paulo Gustavo, Dizman, Nazli, Jonasch, Eric, Hammers, Hans J., George, Daniel J., Bex, Axel, Ljungberg, Borje, Pal, Sumanta Kumar, Staehler, Michael D.
Publicado 2019

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

por Amin, Asim, Plimack, Elizabeth R, Ernstoff, Marc S, Lewis, Lionel D, Bauer, Todd M, McDermott, David F, Carducci, Michael, Kollmannsberger, Christian, Rini, Brian I, Heng, Daniel Y C, Knox, Jennifer, Voss, Martin H, Spratlin, Jennifer, Berghorn, Elmer, Yang, Lingfeng, Hammers, Hans J
Publicado 2018

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

por Amin, Asim, Plimack, Elizabeth R., Ernstoff, Marc S., Lewis, Lionel D., Bauer, Todd M., McDermott, David F., Carducci, Michael, Kollmannsberger, Christian, Rini, Brian I., Heng, Daniel Y. C., Knox, Jennifer, Voss, Martin H., Spratlin, Jennifer, Berghorn, Elmer, Yang, Lingfeng, Hammers, Hans J.
Publicado 2019

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade

por Naidoo, Jarushka, Cappelli, Laura C., Forde, Patrick M., Marrone, Kristen A., Lipson, Evan J., Hammers, Hans J., Sharfman, William H., Le, Dung T., Baer, Alan N., Shah, Ami A., Albayda, Jemima, Manno, Rebecca L., Haque, Uzma, Gutierrez, Anna Kristina, Bingham, Clifton O., Brahmer, Julie R.
Publicado 2017

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

por Regan, Meredith M., Jegede, Opeyemi A., Mantia, Charlene M., Powles, Thomas, Werner, Lillian, Motzer, Robert J., Tannir, Nizar M., Lee, Chung-Han, Tomita, Yoshihiko, Voss, Martin H., Plimack, Elizabeth R., Choueiri, Toni K., Rini, Brian I., Hammers, Hans J., Escudier, Bernard, Albiges, Laurence, Huo, Stephen, Del Tejo, Viviana, Stwalley, Brian, Atkins, Michael B., McDermott, David F.
Publicado 2021

A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience

por Costello, Brian A., Bhavsar, Nrupen A., Zakharia, Yousef, Pal, Sumanta K., Vaishampayan, Ulka, Jim, Heather, Fishman, Mayer N., Molina, Ana M., Kyriakopoulos, Christos E., Tsao, Che-Kai, Appleman, Leonard J., Gartrell, Benjamin A., Hussain, Arif, Stadler, Walter M., Agarwal, Neeraj, Pachynski, Russell K., Hutson, Thomas E., Hammers, Hans J., Ryan, Christopher W., Mardekian, Jack, Borham, Azah, George, Daniel J., Harrison, Michael R.
Publicado 2022

Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)

por Harrison, Michael R., Costello, Brian A., Bhavsar, Nrupen A., Vaishampayan, Ulka, Pal, Sumanta K., Zakharia, Yousef, Jim, Heather S. L., Fishman, Mayer N., Molina, Ana M., Kyriakopoulos, Christos E., Tsao, Che‐Kai, Appleman, Leonard J., Gartrell, Benjamin A., Hussain, Arif, Stadler, Walter M., Agarwal, Neeraj, Pachynski, Russell K., Hutson, Thomas E., Hammers, Hans J., Ryan, Christopher W., Inman, Brant A., Mardekian, Jack, Borham, Azah, George, Daniel J.
Publicado 2021

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

por Motzer, Robert J., McDermott, David F., Escudier, Bernard, Burotto, Mauricio, Choueiri, Toni K., Hammers, Hans J., Barthélémy, Philippe, Plimack, Elizabeth R., Porta, Camillo, George, Saby, Powles, Thomas, Donskov, Frede, Gurney, Howard, Kollmannsberger, Christian K., Grimm, Marc‐Oliver, Barrios, Carlos, Tomita, Yoshihiko, Castellano, Daniel, Grünwald, Viktor, Rini, Brian I., McHenry, M. Brent, Lee, Chung‐Wei, McCarthy, Jennifer, Ejzykowicz, Flavia, Tannir, Nizar M.
Publicado 2022

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a random...

por Motzer, Robert J, Escudier, Bernard, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Powles, Thomas, Donskov, Frede, Plimack, Elizabeth R, Barthélémy, Philippe, Hammers, Hans J, George, Saby, Grünwald, Viktor, Porta, Camillo, Neiman, Victoria, Ravaud, Alain, Choueiri, Toni K, Rini, Brian I, Salman, Pamela, Kollmannsberger, Christian K, Tykodi, Scott S, Grimm, Marc-Oliver, Gurney, Howard, Leibowitz-Amit, Raya, Geertsen, Poul F, Amin, Asim, Tomita, Yoshihiko, McHenry, M Brent, Saggi, Shruti Shally, Tannir, Nizar M
Publicado 2021